Synthesis of Nitroalkanes from Alkylhalides under Mild and Nonaqueous Conditions by Using Polymer Supported Nitrites
作者:Mohammad Ali Karimi Zarchi、Amin Zarei
DOI:10.1002/jccs.200500047
日期:2005.4
Alkyl halides are efficiently converted to their corresponding nitroalkanesundermild and nonaqueousconditions by usingpolymersupportednitrites. The polymeric reagent is regenerable.
The present invention provides a compound of Formula (I)
or a pharmaceutically acceptable salt thereof wherein R
1
, R
2
, R
3
, A
1
, A
2
, A
3
, A
4
, L, B
1
, B
2
, B
3
and B
4
are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
A highly diastereo- and enantioselective nitro-Mannich reaction of isatin-derived ketimines with α-aryl nitromethane catalyzed by Cinchona alkaloid-derived phase-transfercatalysts bearing multiple hydrogen-bonding donors (the first metal-free catalytic systems used in this reaction) was developed. A series of 3-substituted 3-amino-oxindoles were constructed using this protocol in excellent yields
L-tert-Leucine derived urea-ammonium salts: Efficient bifunctional phase transfer catalysts for highly diastereo- and enantioselective aza-Henry reaction of isatin-derived N-Boc ketimines with α-aryl nitromethanes
efficient way of aza-Henry reaction between isatin-derived N-Boc ketimines and α-aryl nitromethanes catalyzed by bifunctional phase transfer catalysts with a quaternary ammonium center derived from L-tert-Leucine has been developed. A series of 3-substituted 3-amino-oxindoles were constructed by this catalytic protocol in excellent yields (90–99%), with high enantioselectivities (83–95%) and diastereoselectivities
[EN] ARYL-SUBSTITUTED IMIDAZOLES AND METHODS OF MAKING AND USING SAME<br/>[FR] IMIDAZOLES SUBSTITUÉS PAR UN ARYL ET LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
申请人:ST JUDE CHILDRENS RES HOSPITAL
公开号:WO2015184383A1
公开(公告)日:2015-12-03
The compounds of the invention are antagonists of MDM2 and/or MDMX, with excellent specificity for MDM2 and/or MDMX over other proteins. Several analogs demonstrate selective binding affinity to MDMX over MDM2. The disclosed compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.